Targeting the endocannabinoid system in diabesity: fact or fiction?

'Diabesity' refers to a rising epidemic indicated by the intricate relationship between obesity and diabetes. The global prevalence of these coexisting, insidious diseases increases social and economic health burdens at a rapid pace. Numerous reports delineate the involvement of the underlying endocannabinoid (EC) signaling system through the cannabinoid-1 (CB1) receptor in the regulation of metabolism and adiposity. Conversely, EC inverse agonists can result in severe depression and suicidal thoughts through interactions with CB1/2 receptors in the brain. This review attempts to elucidate a possible mechanism for the amelioration of diabesity. Moreover, we also highlight the available targets of the CB1 receptor, which could pave the way for safe and effective therapy.

• Publication year

  2021

• Venue

  Drug Discovery Today

• Publication date

  2021-03-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.drudis.2021.03.022PMID 33781949
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The therapeutic potential of second and third generation CB1R antagonists.

  2020cited by this paper
• Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research

  2020cited by this paper
• Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs

  2020cited by this paper
• The fundamental role of the endocannabinoid system in endometrium and placenta: implications in pathophysiological aspects of uterine and pregnancy disorders

  2020cited by this paper
• Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice

  2020cited by this paper
• Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol

  2020cited by this paper
• A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain

  2020cited by this paper
• Changing the Tone of Clinical Study Design in the Cannabis Industry

  2020cited by this paper
• Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes

  2020cited by this paper
• Predicting the Blood-Brain Barrier Permeability of New Drug-Like Compounds via HPLC with Various Stationary Phases

  2020cited by this paper
• Molecular Interaction between Distal C-Terminal Domain of the CB1 Cannabinoid Receptor and Cannabinoid Receptor Interacting Proteins (CRIP1a/CRIP1b)

  2019cited by this paper
• Insulin analogs: Glimpse on contemporary facts and future prospective

  2019cited by this paper
• Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow

  2019cited by this paper
• Medical marijuana—an obesity problem or opportunity?

  2019cited by this paper
• A patent update on cannabinoid receptor 1 antagonists (2015-2018)

  2019cited by this paper
• Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials

  2019cited by this paper
• Development of Oxygen-Bridged Pyrazole-Based Structures as Cannabinoid Receptor 1 Ligands

  2019cited by this paper
• Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications

  2019cited by this paper
• Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome

  2019cited by this paper
• Cannabinoid CB1 Receptors Inhibit Gut-Brain Satiation Signaling in Diet-Induced Obesity

  2019cited by this paper
• Adipose Tissue-Derived Signatures for Obesity and Type 2 Diabetes: Adipokines, Batokines and MicroRNAs

  2019cited by this paper
• Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes

  2019cited by this paper
• Friendly Fat Theory – Explaining the Paradox of Diabetes and Obesity

  2019cited by this paper
• Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: Current approaches for therapeutics development.

  2019cited by this paper
• Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use

  2019cited by this paper
• Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity‐induced chronic kidney disease

  2019cited by this paper
• New insights into different adipokines in linking the pathophysiology of obesity and psoriasis

  2019cited by this paper
• Preclinical toxicity evaluation of JD5037, a peripherally restricted CB1 receptor inverse agonist, in rats and dogs for treatment of nonalcoholic steatohepatitis.

  2019cited by this paper
• The Latest Insights into Adipokines in Diabetes

  2019cited by this paper
• Relevance of Leptin and Other Adipokines in Obesity-Associated Cardiovascular Risk

  2019cited by this paper
• Allosteric Modulation of Cannabinoid Receptor 1—Current Challenges and Future Opportunities

  2019cited by this paper
• Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists

  2018cited by this paper
• The therapeutic potential of targeting the peripheral endocannabinoid/CB1 receptor system.

  2018cited by this paper
• No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

  2018cited by this paper
• Contribution of Adipose Tissue Inflammation to the Development of Type 2 Diabetes Mellitus.

  2018cited by this paper
• Combined and individual strategy of exercise generated preconditioning and low dose copper nanoparticles serve as superlative approach to ameliorate ISO-induced myocardial infarction in rats

  2018cited by this paper
• Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis.

  2017cited by this paper
• Metabolic Profiling of CB1 Neutral Antagonists.

  2017cited by this paper
• Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis.

  2017cited by this paper
• Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease

  2017cited by this paper
• Albiglutide: Is a better hope against diabetes mellitus?

  2016cited by this paper
• Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus.

  2016cited by this paper
• Correction: Prediabetes: grounds of pitfall signalling alteration for cardiovascular disease

  2015cited by this paper
• Endocannabinoid signaling at the periphery: 50 years after THC.

  2015cited by this paper
• Mechanism linking diabetes mellitus and obesity

  2014cited by this paper
• Role of anorectic N-acylethanolamines in intestinal physiology and satiety control with respect to dietary fat.

  2014cited by this paper
• The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity

  2013cited by this paper
• Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ9‐tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats

  2013cited by this paper
• The dysregulation of the endocannabinoid system in diabesity—a tricky problem

  2009cited by this paper
• Leptin controls adipose tissue lipogenesis via central, STAT3–independent mechanisms

  2008cited by this paper
• Hypothalamic control of hepatic glucose production and its potential role in insulin resistance.

  2008cited by this paper
• Brain–adipose tissue cross talk

  2005cited by this paper
• Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.

  1995cited by this paper
• 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain.

  1995cited by this paper
• Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

  1992cited by this paper

• Genetic-epigenetic targets for PCOS-associated diabesity.

  2025cites this paper
• Amelioration of endothelial integrity by 3,5,4'-trihydroxy-trans-stilbene against high-fat-diet-induced obesity and -associated vasculopathy and myocardial infarction in rats, targeting TLR4/MyD88/NF-κB/iNOS signaling cascade.

  2024cites this paper
• Identification of different extracts and phytoconstituents of Callistemon viminalis Cheel for their anti-anxiety effects based on pharmacognostic, toxicological, and pharmacological strategies

  2024cites this paper
• Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile

  2024cites this paper
• Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity

  2023cites this paper
• Dysbiosis versus diabesity: pathological signaling and promising therapeutic strategies.

  2023cites this paper
• Novel cannabinoid receptor 1 inverse agonist CRB‐913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet‐induced obesity mouse model

  2023cites this paper
• Molecular basis of phytochemical-gut microbiota interactions.

  2023cites this paper
• Cross-Talk between the (Endo)Cannabinoid and Renin-Angiotensin Systems: Basic Evidence and Potential Therapeutic Significance

  2022cites this paper
• Preliminary investigation on impact of intergenerational treatment of resveratrol endorses the development of 'super-pups'.

  2022cites this paper
• Comparative study of CNR1 and CNR2 cannabinoid receptors expression levels in COVID-19 patients with and without diabetes mellitus: Recommendations for future research targets

  2022cites this paper
• Synthesis, molecular docking, and pharmacological evaluation of 5-(4-(2-(5-ethyl pyridine-2-yl) ethoxy) benzyl)-3-(phenylsulfonyl) thiazolidine-2, 4-dione against HFD-induced diabesity via interaction with the CB1 receptor

  2022influential citation
• Endocannabinoid-Binding Receptors as Drug Targets.

  year unknowncites this paper